Fibe Aims for ₹1,500 Crore IPO, Eyes Billion-Dollar Valuation by 2026...
08 Aug, 2025
Mumbai-based Influx Healthtech Limited, a fast-growing contract development and manufacturing organization (CDMO) in the healthcare sector, has filed its Draft Red Herring Prospectus (DRHP) for an SME initial public offering (IPO) on NSE Emerge. The IPO, set to open on June 18 and close on June 20, 2025, aims to raise approximately ₹58.57 crore through a combination of fresh issue and offer for sale.
The IPO includes a fresh issue of up to 50,00,400 equity shares to raise ₹48 crore and an offer for sale of up to 11,00,400 equity shares by the promoters. The price band is set at ₹91 to ₹96 per share with a face value of ₹10 per share. The minimum application lot is 1,200 shares, requiring a retail investment of at least ₹1,15,200. The issue is structured as a book-building process with allocations set at up to 50% for qualified institutional buyers (QIBs), 15% for non-institutional investors (NIIs) and 35% for retail investors.
Rarever Financial Advisors Private Limited is the sole lead manager for the issue and Maashitla Securities Private Limited is appointed as the registrar.
Founded in 2020 by Munir Abdul Ganee Chandniwala, Influx Healthtech has quickly established itself as a key player in the CDMO space, specializing in dietary supplements, cosmetics and veterinary feed supplements. The company operates from Thane, Maharashtra and serves a diverse client base, including Bling Brands Private Limited and Evoq Business Ventures LLP.
Influx Healthtech’s business model focuses on contract development and manufacturing, catering to the growing demand for health, wellness and veterinary products. The company’s product portfolio includes nutraceuticals, home care, cosmetics and veterinary food supplements that align with industry trends toward increased health awareness and preventive care.
The proceeds from the fresh issue will be utilized to expand manufacturing capacity across three key divisions of the company. A sum of ₹13.23 crore will be allocated to the Nutraceutical Division to enhance its production capabilities. The Veterinary Food Division will receive ₹4.10 crore for capacity expansion, while ₹2.75 crore will be directed towards the Homecare and Cosmetic Division to support its growth and development.
This expansion aims to enhance production capabilities and support the company’s growth and diversification strategy.
Influx Healthtech has shown strong financial growth since its inception. In FY23, the company reported a revenue of ₹76.06 crore with a profit after tax of ₹7.20 crore. This performance improved significantly in FY24 with revenue rising to ₹100.10 crore and profit after tax increasing to ₹11.22 crore. The upward trend continued in FY25 as revenue further climbed to ₹104.99 crore and profit after tax reached ₹13.37 crore. The company’s strong financial position is further highlighted by its FY25 metrics which include a return on equity (ROE) of 36.98%, a return on capital employed (ROCE) of 49.17% and a PAT margin of 12.75%. Additionally, a low debt-to-equity ratio of 0.01 also reflects the company’s careful financial management.
The Indian CDMO sector is witnessing rapid growth driven by rising demand for health supplements, preventive healthcare and veterinary products. Influx Healthtech’s expansion plans are appropriate to capitalize on these trends. The company faces competition from established players in pharmaceuticals and nutraceuticals but its focus on diversified product lines and contract manufacturing offers a strong value proposition.
Influx Healthtech’s SME IPO represents a significant step in its growth journey, providing capital for expansion and offering investors an opportunity to participate in India’s dynamic healthcare manufacturing sector. With a proven track record, strong financials and ambitious expansion plans, the company is well-positioned to benefit from the evolving landscape of health and wellness in India.
Read more :
